SAN JOSE, Calif., June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends." Both the New York Post and Fox News highlighted the potential of Anixa's vaccine to change the paradigm for breast cancer tr ...

Core Viewpoint - Anixa Biosciences Inc (ANIX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance Indicators - Anixa Biosciences is projected to earn -$0.38 per share for the fiscal year ending October 2025, reflecting a year-over-year change of 2.6% [7]. - Over the past three months, the Zacks Consensus Estimate for Anixa has increased by 7.3%, indicating a positive revision trend [7]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6][8]. - Anixa's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Company Overview - ANIXA BIOSCIENCES INC is part of the Medical group, which consists of 999 companies and is currently ranked 4 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 503 companies and is ranked 78 in the Zacks Industry Rank [5] Performance Metrics - Year-to-date, ANIXA BIOSCIENCES INC has increased by approximately 20.3%, outperforming the average loss of 4.4% in the Medical group [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has risen by 7.3% over the past quarter, indicating improved analyst sentiment and earnings outlook [3] Comparative Analysis - Another outperforming stock in the Medical sector is Cellectar Biosciences, Inc., which has returned 54.4% year-to-date [4] - Cellectar Biosciences, Inc. belongs to the Medical - Products industry, which has a lower ranking (134) and has increased by 5.2% this year [6]

Revenue - No revenue was generated during the three-month and six-month periods ended April 30, 2025 and 2024[84][92] Expenses - Research and development expenses decreased by approximately $324,000 to approximately $1,322,000 in the three months ended April 30, 2025, compared to approximately $1,646,000 in the same period of 2024[87] - General and administrative expenses decreased by approximately $140,000 to approximately $1,681,000 in the three months ended April 30, 2025, from approximately $1,821,000 in the same period of 2024[88] - Research and development expenses for cancer vaccines and CAR-T therapeutics were approximately $1,873,000 and $1,001,000, respectively, during the six months ended April 30, 2025[94] - General and administrative expenses decreased by approximately $566,000 to approximately $3,515,000 in the six months ended April 30, 2025, from approximately $4,081,000 in the same period of 2024[96] Income - Interest income decreased by approximately $96,000 to approximately $190,000 in the three months ended April 30, 2025, from approximately $287,000 in the same period of 2024[89] - Interest income decreased by approximately $243,000 to approximately $363,000 in the six months ended April 30, 2025, from approximately $606,000 in the same period of 2024[97] Assets and Cash Flow - Total current assets decreased by approximately $4,596,000 to approximately $16,766,000 at April 30, 2025, compared to approximately $21,362,000 at October 31, 2024[100] - Cash used in operating activities was approximately $4,407,000 during the six months ended April 30, 2025[101] Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $24,000 to approximately $52,000 in the six months ended April 30, 2025, from approximately $76,000 in the same period of 2024[98] Internal Controls - There was no change in internal control over financial reporting during the three months ended April 30, 2025, that materially affected internal control[117] - The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures are effective as of the end of the reporting period[116] Compensation Allocation - The company allocates certain internal compensation costs to research and development expenses based on management's estimates of employee time and effort[113]

Financial Data and Key Metrics Changes - The company has a strong balance sheet with $17 million in cash, providing a runway of approximately 2.5 years, which is considered ample in the current industry context [6][9][13] - Historical cash burn averages between $5 million and $7 million per year, indicating a capital-efficient business model [8][15] Business Line Data and Key Metrics Changes - The company is advancing two lead clinical programs: a breast cancer vaccine and an ovarian cancer CAR T therapy, both currently in Phase 1 clinical trials with promising clinical data [3][16] - The breast cancer vaccine is funded by a U.S. Government grant, which helps keep cash burn low [17][34] Market Data and Key Metrics Changes - The breast cancer market is large and well-known, while the ovarian cancer market, though smaller, presents a significant unmet medical need with poor outcomes [5] - The company is targeting both neoadjuvant and primary prevention markets for its breast cancer vaccine, indicating a broad market strategy [40] Company Strategy and Development Direction - The company leverages partnerships with top-tier academic institutions like Moffitt Cancer Center and Cleveland Clinic to enhance its research capabilities without incurring high costs [4][10] - The strategy focuses on advancing clinical programs through early stages and partnering with pharmaceutical companies for later-stage development and commercialization [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical data being generated, particularly regarding the safety and efficacy of the ovarian cancer CAR T therapy, with encouraging survival rates observed in treated patients [27][28] - The company aims to present final data from the Phase 1 trial of the breast cancer vaccine at the San Antonio Breast Cancer Symposium in December, indicating a proactive approach to sharing results [39] Other Important Information - The company has maintained consistent insider buying over the years, reflecting management's confidence in the business [7] - There are no outstanding warrants, preferred stock, or debt, which positions the company favorably for future financing [13] Q&A Session Summary Question: What is the current status of the ovarian cancer CAR T therapy? - The therapy is in Phase 1 trials, with encouraging safety profiles and overall survival rates observed in treated patients [27][28] Question: How is the breast cancer vaccine funded? - The breast cancer vaccine is fully funded by a U.S. Government grant, which helps minimize cash burn [17][34] Question: What are the next steps for the breast cancer vaccine program? - The company plans to present final data from the Phase 1 trial at the San Antonio Breast Cancer Symposium in December and is preparing for a Phase 2 trial [39][40]

Group 1 - Anixa Biosciences, Inc. is participating in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at Nasdaq World Headquarters in New York City [1][2] - Mike Catelani, President and CFO of Anixa, will present and be available for one-on-one meetings during the conference [1][2] - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] Group 2 - The company's vaccine portfolio includes vaccines for breast and ovarian cancer developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - Anixa's business model involves partnerships with renowned research institutions at all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [2]

Core Viewpoint - Anixa Biosciences (ANIX) shares rose by 13% following the announcement of a new patent for its breast cancer vaccine technology, developed in collaboration with Cleveland Clinic, which is currently in early-stage studies [1][4]. Group 1: Patent and Technology - The new patent broadens the immunogenic compositions for Anixa's breast cancer vaccine, focusing on the human α-lactalbumin protein, which is present in breast tissue during lactation and expressed in certain breast cancers, making it a viable target for immunoprevention [2]. - The patent enhances Anixa's intellectual property portfolio, emphasizing the uniqueness of its investigational breast cancer vaccine, thereby strengthening the company's competitive position [4]. Group 2: Clinical Trials and Future Plans - The ongoing phase I study is assessing the breast cancer vaccine's maximum tolerated dose and immune response in patients with early-stage, triple-negative breast cancer, showing antigen-specific immune responses and a favorable safety profile [5]. - Based on positive findings, Anixa plans to initiate a phase II study in 2025 to evaluate the vaccine's therapeutic effect in a pre-surgery setting for breast cancer [5]. Group 3: Collaborations and Other Developments - Anixa is collaborating with Cleveland Clinic on additional vaccines targeting ovarian, lung, colon, and prostate cancers, which are currently in pre-clinical or discovery stages [7]. - The innovative vaccine technologies have a unique mechanism of action, potentially offering therapeutic benefits over existing treatments, with Cleveland Clinic entitled to royalties from their development [8]. - Anixa is also developing an immunotherapy candidate for ovarian cancer in partnership with Moffitt Cancer Center, currently in a phase I study [9].

Core Points - Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology, which broadens the scope of immunogenic compositions used in the vaccine [1][2] - The patent covers methods of immunizing patients against breast cancer using an immunogenic composition containing the human α-lactalbumin protein, which is expressed in certain breast cancers [2] - The CEO of Anixa highlighted that this patent enhances the company's intellectual property portfolio, which includes multiple issued and pending patents in the U.S. and internationally [3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [3] - The company's vaccine portfolio includes vaccines for breast and ovarian cancer, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - Anixa's business model involves partnerships with renowned research institutions, allowing the company to explore emerging technologies for further development and commercialization [3]

Core Viewpoint - Anixa Biosciences, Inc. is participating in the Jones Las Vegas Healthcare and Technology Innovation Conference, highlighting its focus on cancer treatment and prevention [1][2]. Group 1: Conference Details - The conference will take place on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada [1]. - Mike Catelani, President and CFO of Anixa, will present on April 9, 2025, at 4:30 PM PT and will be available for one-on-one meetings [2]. - The event aims to facilitate direct dialogue between innovative companies and institutional investors through various formats including presentations and networking events [2]. Group 2: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4]. - Anixa's business model involves partnerships with renowned research institutions, allowing for continuous exploration of emerging technologies for development and commercialization [4].

Core Viewpoint - Anixa Biosciences has entered into a letter of intent with VERDI Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients, leveraging advanced technology and real-world data to enhance treatment accessibility and efficacy [1][5]. Group 1: Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes immunotherapy programs and various cancer vaccines developed in collaboration with renowned research institutions [8][9]. - VERDI Solutions, based in Vienna, Austria, is pioneering personalized cancer treatment by utilizing artificial intelligence and cloud computing to create tailored cancer vaccines, making them more accessible to patients [2]. Group 2: Technology and Innovation - VERDI's cloud-computing platform allows for rapid development of personalized peptide vaccines based on individual patient data, aiming to improve treatment outcomes through companion diagnostics [2][6]. - The company has successfully administered personalized vaccines to three patients with bone metastases, resulting in significant pain relief and improved quality of life, indicating the potential of its platform [4][6]. Group 3: Regulatory and Market Context - In some European countries, oncologists can prescribe personalized cancer vaccines under the Individueller Heilversuch, providing a pathway for broader patient access and valuable real-world efficacy data [3]. - The increasing recognition of real-world evidence by global regulatory agencies supports the development and commercialization of personalized cancer vaccines, positioning VERDI as a leader in this innovative approach [3]. Group 4: Strategic Collaboration - The letter of intent grants Anixa a six-month exclusive right to negotiate for the research, development, and commercialization of VERDI's cancer vaccines, aligning with Anixa's strategy for a capital-efficient business model in personalized cancer care [5][7].